O	0	10	Randomized
O	11	21	controlled
O	22	27	trial
O	28	30	of
B-intervention	31	41	toremifene
O	42	45	120
O	46	48	mg
O	49	57	compared
O	58	62	with
B-control	63	73	exemestane
O	74	76	25
O	77	79	mg
O	80	85	after
O	86	91	prior
O	92	101	treatment
O	102	106	with
O	107	108	a
O	109	112	non
O	112	113	-
O	113	122	steroidal
O	123	132	aromatase
O	133	142	inhibitor
O	143	145	in
B-eligibility	146	160	postmenopausal
I-eligibility	161	166	women
I-eligibility	167	171	with
I-eligibility	172	179	hormone
I-eligibility	180	188	receptor
I-eligibility	188	189	-
I-eligibility	189	197	positive
I-eligibility	198	208	metastatic
I-eligibility	209	215	breast
I-eligibility	216	222	cancer
O	222	223	.

O	224	229	After
O	230	233	the
O	234	241	failure
O	242	244	of
O	245	246	a
O	247	250	non
O	250	251	-
O	251	260	steroidal
O	261	270	aromatase
O	271	280	inhibitor
O	281	282	(
O	282	286	nsAI
O	286	287	)
O	288	291	for
O	292	306	postmenopausal
O	307	315	patients
O	316	320	with
O	321	331	metastatic
O	332	338	breast
O	339	345	cancer
O	346	347	(
O	347	350	mBC
O	350	351	)
O	351	352	,
O	353	355	it
O	356	358	is
O	359	366	unclear
O	367	372	which
O	373	375	of
O	376	383	various
O	384	389	kinds
O	390	392	of
O	393	402	endocrine
O	403	410	therapy
O	411	413	is
O	414	417	the
O	418	422	most
O	423	434	appropriate
O	434	435	.

O	436	437	A
O	438	448	randomized
O	449	459	controlled
O	460	465	trial
O	466	469	was
O	470	479	performed
O	480	482	to
O	483	490	compare
O	491	494	the
O	495	503	efficacy
O	504	507	and
O	508	514	safety
O	515	517	of
O	518	523	daily
O	524	534	toremifene
O	535	538	120
O	539	541	mg
O	542	543	(
O	543	549	TOR120
O	549	550	)
O	550	551	,
O	552	553	a
O	554	563	selective
O	564	572	estrogen
O	573	581	receptor
O	582	591	modulator
O	591	592	,
O	593	596	and
O	597	607	exemestane
O	608	610	25
O	611	613	mg
O	614	615	(
O	615	618	EXE
O	618	619	)
O	619	620	,
O	621	622	a
O	623	632	steroidal
O	633	642	aromatase
O	643	652	inhibitor
O	652	653	.

O	654	657	The
O	658	665	primary
O	666	669	end
O	670	675	point
O	676	679	was
O	680	683	the
B-outcome-Measure	684	692	clinical
I-outcome-Measure	693	700	benefit
I-outcome-Measure	701	705	rate
I-outcome-Measure	706	707	(
I-outcome-Measure	707	710	CBR
I-outcome-Measure	710	711	)
O	711	712	.

O	713	716	The
O	717	726	secondary
O	727	730	end
O	731	737	points
O	738	742	were
B-outcome-Measure	743	752	objective
I-outcome-Measure	753	761	response
I-outcome-Measure	762	766	rate
I-outcome-Measure	767	768	(
I-outcome-Measure	768	771	ORR
I-outcome-Measure	771	772	)
O	772	773	,
B-outcome-Measure	774	785	progression
I-outcome-Measure	785	786	-
I-outcome-Measure	786	790	free
I-outcome-Measure	791	799	survival
I-outcome-Measure	800	801	(
I-outcome-Measure	801	804	PFS
I-outcome-Measure	804	805	)
O	805	806	,
B-outcome-Measure	807	814	overall
I-outcome-Measure	815	823	survival
I-outcome-Measure	824	825	(
I-outcome-Measure	825	827	OS
I-outcome-Measure	827	828	)
O	829	832	and
B-outcome-Measure	833	841	toxicity
O	841	842	.

O	843	852	Initially
O	852	853	,
O	854	855	a
O	856	861	total
O	862	864	of
B-total-participants	865	867	91
O	868	873	women
O	874	877	was
O	878	888	registered
O	889	891	in
O	892	895	the
O	896	901	study
O	902	905	and
O	906	914	randomly
O	915	923	assigned
O	924	926	to
O	927	933	either
O	934	940	TOR120
O	941	942	(
O	942	943	n
O	944	945	=
B-intervention-participants	946	948	46
O	948	949	)
O	950	952	or
O	953	956	EXE
O	957	958	(
O	958	959	n
O	960	961	=
B-control-participants	962	964	45
O	964	965	)
O	966	970	from
O	971	978	October
O	979	983	2008
O	984	986	to
O	987	995	November
O	996	1000	2011
O	1000	1001	.

O	1002	1007	Three
O	1008	1010	of
O	1011	1014	the
O	1015	1017	46
O	1018	1026	patients
O	1027	1029	in
O	1030	1033	the
O	1034	1040	TOR120
O	1041	1044	arm
O	1045	1049	were
O	1050	1053	not
O	1054	1062	received
O	1063	1072	treatment
O	1072	1073	,
O	1074	1075	2
O	1076	1084	patients
O	1085	1091	having
O	1092	1101	withdrawn
O	1102	1106	from
O	1107	1110	the
O	1111	1116	trial
O	1117	1119	by
O	1120	1125	their
O	1126	1136	preference
O	1137	1140	and
O	1141	1144	one
O	1145	1151	having
O	1152	1156	been
O	1157	1164	dropped
O	1165	1168	due
O	1169	1171	to
O	1172	1186	administration
O	1187	1189	of
O	1190	1197	another
O	1198	1202	SERM
O	1202	1203	.

O	1204	1208	When
O	1209	1217	analyzed
O	1218	1223	after
O	1224	1225	a
O	1226	1232	median
O	1233	1244	observation
O	1245	1251	period
O	1252	1254	of
O	1255	1257	16
O	1257	1258	.
O	1258	1259	9
O	1260	1266	months
O	1266	1267	,
O	1268	1271	the
O	1272	1281	intention
O	1281	1282	-
O	1282	1284	to
O	1284	1285	-
O	1285	1290	treat
O	1291	1299	analysis
O	1300	1306	showed
O	1307	1311	that
O	1312	1317	there
O	1318	1322	were
O	1323	1325	no
O	1326	1337	statistical
O	1338	1348	difference
O	1349	1356	between
O	1357	1363	TOR120
O	1364	1365	(
O	1365	1366	N
O	1367	1368	=
B-intervention-participants	1369	1371	46
O	1371	1372	)
O	1373	1376	and
O	1377	1380	EXE
O	1381	1382	(
O	1382	1383	n
O	1384	1385	=
B-control-participants	1386	1388	45
O	1388	1389	)
O	1390	1392	in
O	1393	1398	terms
O	1399	1401	of
B-outcome	1402	1405	CBR
O	1406	1407	(
B-iv-bin-percent	1407	1409	41
I-iv-bin-percent	1409	1410	.
I-iv-bin-percent	1410	1411	3
I-iv-bin-percent	1411	1412	%
O	1413	1415	vs
O	1415	1416	.
B-cv-bin-percent	1417	1419	26
I-cv-bin-percent	1419	1420	.
I-cv-bin-percent	1420	1421	7
I-cv-bin-percent	1421	1422	%
O	1422	1423	;
O	1424	1425	P
O	1426	1427	=
O	1428	1429	0
O	1429	1430	.
O	1430	1432	14
O	1432	1433	)
O	1433	1434	,
B-outcome	1435	1438	ORR
O	1439	1440	(
B-iv-bin-percent	1440	1442	10
I-iv-bin-percent	1442	1443	.
I-iv-bin-percent	1443	1444	8
I-iv-bin-percent	1444	1445	%
O	1446	1448	vs
O	1448	1449	.
B-cv-bin-percent	1450	1451	2
I-cv-bin-percent	1451	1452	.
I-cv-bin-percent	1452	1453	2
I-cv-bin-percent	1453	1454	%
O	1454	1455	;
O	1456	1457	P
O	1458	1459	=
O	1460	1461	0
O	1461	1462	.
O	1462	1465	083
O	1465	1466	)
O	1466	1467	,
O	1468	1471	and
B-outcome	1472	1474	OS
O	1475	1476	(
O	1476	1482	Hazard
O	1483	1488	ratio
O	1488	1489	,
O	1490	1491	0
O	1491	1492	.
O	1492	1494	60
O	1494	1495	;
O	1496	1497	P
O	1498	1499	=
O	1500	1501	0
O	1501	1502	.
O	1502	1504	22
O	1504	1505	)
O	1505	1506	.

O	1507	1510	The
B-outcome	1511	1514	PFS
O	1515	1517	of
O	1518	1524	TOR120
O	1525	1528	was
O	1529	1535	longer
O	1536	1540	than
O	1541	1545	that
O	1546	1548	of
O	1549	1552	EXE
O	1552	1553	,
O	1554	1557	the
O	1558	1568	difference
O	1569	1574	being
O	1575	1588	statistically
O	1589	1600	significant
O	1601	1602	(
O	1602	1608	Hazard
O	1609	1614	ratio
O	1614	1615	,
O	1616	1617	0
O	1617	1618	.
O	1618	1620	61
O	1620	1621	,
O	1622	1623	P
O	1624	1625	=
O	1626	1627	0
O	1627	1628	.
O	1628	1631	045
O	1631	1632	)
O	1632	1633	.

O	1634	1637	The
O	1638	1645	results
O	1646	1648	in
O	1649	1658	treatment
O	1658	1659	-
O	1659	1667	received
O	1668	1674	cohort
O	1675	1676	(
O	1676	1677	N
O	1678	1679	=
O	1680	1682	88
O	1682	1683	)
O	1684	1688	were
O	1689	1696	similar
O	1697	1699	to
O	1700	1705	those
O	1706	1708	in
O	1709	1712	ITT
O	1713	1719	cohort
O	1719	1720	.

O	1721	1725	Both
O	1726	1736	treatments
O	1737	1741	were
O	1742	1746	well
O	1746	1747	-
O	1747	1756	tolerated
O	1757	1761	with
O	1762	1764	no
O	1765	1771	severe
B-outcome	1772	1779	adverse
I-outcome	1780	1786	events
O	1786	1787	,
O	1788	1796	although
O	1797	1800	the
O	1801	1810	treatment
O	1811	1813	of
B-iv-bin-abs	1814	1815	3
O	1816	1818	of
B-intervention-participants	1819	1821	43
O	1822	1827	women
O	1828	1840	administered
O	1841	1847	TOR120
O	1848	1851	was
O	1852	1859	stopped
O	1860	1865	after
O	1866	1867	a
O	1868	1871	few
O	1872	1876	days
O	1877	1884	because
O	1885	1887	of
O	1888	1894	nausea
O	1894	1895	,
O	1896	1903	general
O	1904	1911	fatigue
O	1911	1912	,
O	1913	1916	hot
O	1917	1922	flush
O	1923	1926	and
O	1927	1932	night
O	1933	1941	sweating
O	1941	1942	.

O	1943	1949	TOR120
O	1949	1950	,
O	1951	1953	as
O	1954	1955	a
O	1956	1966	subsequent
O	1967	1976	endocrine
O	1977	1984	therapy
O	1985	1988	for
O	1989	1992	mBC
O	1993	2001	patients
O	2002	2005	who
O	2006	2012	failed
O	2013	2016	non
O	2016	2017	-
O	2017	2026	steroidal
O	2027	2029	AI
O	2030	2039	treatment
O	2039	2040	,
O	2041	2046	could
O	2047	2058	potentially
O	2059	2061	be
O	2062	2066	more
O	2067	2077	beneficial
O	2078	2082	than
O	2083	2086	EXE
O	2086	2087	.

O	2088	2101	UMIN000001841
O	2101	2102	.
